Bristol-Myers: A Massive Would-Be Takeover

Carl Icahn is getting more interested in biotech, notably Bristol-Myers Squibb (NYSE:BMY). For starters, Icahn has a stake in BMY, although it's unclear how much. And now he has brought on a biotech expert to help run his fund. Icahn hired Harvard geneticist Richard Mulligan as a portfolio manager. Mulligan has worked with Icahn in the past, and was a managing director at Icahn protege Alex Denner's Sarissa Capital for the last three years.

The hire signals that Icahn is ready to formally take on the beaten-down biotech space. The iShares Nasdaq Biotech ETF (NASDAQ:IBB) is down some 12% in the last 24 months, while the S&P 500 is up 13%. Meanwhile, BMY has also been an underperformer, with shares down 5% in the same period. The thesis is that the $100 billion drug company might be a buyout target. Generally, the focus is on selling off smaller companies to the larger ones, but Icahn is aiming high here. This comes after Denner left Icahn's firm in 2013.

READ FULL ARTICLE HERE